This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
April 22, 2024
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the 2023 Annual Report has been published.
April 22, 2024
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
April 22, 2024
HealthCap´s co-founder Peder Fredrikson passed away at the age of 72
April 18, 2024
BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for Interim report Q1 2024
April 17, 2024
Oncopeptides publishes prospectus relating to the rights issue
April 15, 2024
Oncopeptides secures national reimbursement for Pepaxti in Spain
April 10, 2024
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
April 09, 2024
Fusion Pharmaceuticals Announces Presentation Of Interim Data From The Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 At The AACR Annual Meeting 2024
April 08, 2024
Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease
April 08, 2024
Oncopeptides announces final terms for the fully guaranteed rights issue